PUBLISHER: Grand View Research | PRODUCT CODE: 1611181
PUBLISHER: Grand View Research | PRODUCT CODE: 1611181
The global next-generation sequencing data analysis market size is estimated to reach USD 3.45 billion by 2030, expanding at a CAGR of 23.10% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth can be attributed to a significant decline in the cost of NGS installation in clinical diagnosis. Furthermore, the accessibility of genomic and proteomic data is anticipated to create significant growth opportunities. In addition, a reduction in the cost of sequencing is anticipated to boost the adoption rate of NGS, which would further drive the industry. The availability of tools, such as the Targeted Methyl-Seq platform and Agilent's HaloPlex capture system from EpiGentek Group Inc. has aided in the DNA methylation profiles determination in individual genomes. The COVID-19 pandemic has enhanced NGS usage and has created a huge demand.
The NGS tools can generate a significant amount of data for scientists to analyze and study pathogenesis. Researchers from industry, academia, and government have used data analysis technology to help in understanding the characteristics, phylogenetics, and processes of SARS-CoV2. NGS technologies have helped to unveil biological information that has not been studied yet using conventional technologies. For instance, NGS has helped study genomic patterns associated with various biological processes and epigenomics. However, issues related to accessing storage management, and analysis of data are anticipated to offer huge R&D prospects, thus, driving the industry growth. Researchers that use high-throughput sequencers demand software systems, such as Laboratory Information Management Systems (LIMS) to archive and handle sequencing information.
Furthermore, the introduction of workflow management system solutions, such as Galaxy and Chipster, drives demand for technological advancements in data storage and management. Demand for technologically advanced infrastructure to monitor the flow of data analysis process from data generation to preliminary analysis to higher-level analysis has increased. Moreover, NGS data analysis tools are being constantly upgraded for obtaining effective results and higher utility. For instance, in December 2021, Bionano Genomics launched BioDiscovery's NxClinical Software Version 6.1 for genome analysis. The version enables enhanced visualization and interpretation of NGS data for cancer and genetic disease domains. Such developments are anticipated to drive the industry over the forecast period.